We examined the potential of hPSC therapy in preventing the onset or attenuating the course of established disease in a murine MS model of myelin oligodendrocyte glycoprotein‐induced experimental autoimmune encephalomyelitis. This evidence concerns the gene OMG and experimental autoimmune encephalomyelitis.